MARKET

CDXS

CDXS

Codexis Inc
NASDAQ
2.900
+0.040
+1.40%
After Hours: 2.960 +0.06 +2.07% 16:09 04/23 EDT
OPEN
2.880
PREV CLOSE
2.860
HIGH
3.030
LOW
2.880
VOLUME
192.44K
TURNOVER
0
52 WEEK HIGH
4.910
52 WEEK LOW
1.450
MARKET CAP
203.88M
P/E (TTM)
-2.5916
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at CDXS last week (0415-0419)?
Weekly Report · 1d ago
Codexis to Report First Quarter 2024 Financial Results on May 2
Codexis, Inc. Will report its financial results for the first quarter of 2024 on May 2, 2024. Management will host a conference call and webcast to discuss the Company's financial results and provide a business update. Codexis is a leading enzyme engineering company.
Barchart · 5d ago
Further weakness as Codexis (NASDAQ:CDXS) drops 11% this week, taking three-year losses to 88%
The share price of Codexis, Inc. Is down 88% in the last three years. The company's shareholders have lost 34% in just the last year. Codexis grew revenue at 4.4% per year, but the company is losing money in pursuit of growth. We like that insiders have been buying shares in the past 12 months. But the company's share price is down 23% in three years, and is down 14% in a month.
Simply Wall St · 04/15 11:06
Weekly Report: what happened at CDXS last week (0408-0412)?
Weekly Report · 04/15 09:18
CODEXIS APPOINTS CAROLE COBB, MBA, TO STRATEGIC ADVISORY BOARD
Reuters · 04/11 11:05
Press Release: Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board
Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board Cobb adds RNA industry operations and commercial expertise to support continued development of ECO Synthesis(TM) manufacturing platform. Ms. Cobb is the former Chief Operating Officer at GreenLight Biosciences. Codexis is a leading enzyme engineering company.
Dow Jones · 04/11 11:05
Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board
Carole Cobb, MBA, is the former Chief Operating Officer at GreenLight Biosciences. Her deep biotechnology experience includes leadership roles in fermentation-based commercial manufacturing. Ms. Cobb joins Codexis' Strategic Advisory Board. Codexis is a leading enzyme engineering company.
Barchart · 04/11 06:05
Weekly Report: what happened at CDXS last week (0401-0405)?
Weekly Report · 04/08 09:20
More
About CDXS
Codexis, Inc. is an enzyme engineering company. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high performance enzymes and other classes of proteins. It utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) therapeutics through an enzymatic route. It also uses the CodeEvolver platform technology to develop enzymes for the synthesis of nucleic acids, such as DNA/RNA, including enzymes utilized in its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.

Webull offers Codexis Inc stock information, including NASDAQ: CDXS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CDXS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CDXS stock methods without spending real money on the virtual paper trading platform.